New Drugs Aim To Move Needle In Tough-to-Treat Acute Myeloid Leukemia

Response rates for candidates from Stemline, Seattle Genetics and Karyopharm look highly encouraging, but the real test in AML will be survival, as the field is still in the shadow of Pfizer's failed Mylotarg.